Senior Management

Chun-Lin Chen Ph.D. Exeutive chairman of Shanghai Medicilon Inc.
Formally a Staff Investigator for Vertex Pharmaceuticals, Dr. Chen co-founded Medicilon in 2004. Dr Chen is a highly published thought leader in the pharmaceutical industry with extensive experience in academia, pharmaceutical, and regulatory evaluation. Dr. Chen received his PhD from Oklahoma State University, and completed postdoctoral training in the United States. He is a Postdoctoral Fellow at the St. Jude Children’s Research Hospital and has held numerous leadership positions in professional scientific trade organizations in China as well as other parts of the world. Dr. Chen is currently CEO of Medicilon/MPI Preclinical Research Shanghai.

Jintao Zhang Ph.D. CEO and co-founder of Shanghai Medicilon Inc.
Prior joining Shanghai Medicilon in 2004, Dr. Zhang was Director of Combinatorial Chemistry at DeCode Genetics Inc., a genetics and health informatics company. Prior to DeCODE’s merger with MediChem Life Sciences in 2002, Dr. Zhang was Director of Combinatorial Chemistry at MediChem. Dr. Zhang received his PhD in Organic Chemistry from the Shanghai Institute of organic chemistry. He performed his postdoctoral fellowships at the University of Chicago. Currently, he is also director of Medicilon MPI Preclinical Research Shanghai.

Nanhorng Lin Ph.D. Vice President of Chemistry, Shanghai Medicilon Inc.
Dr. Lin obtained his Ph.D. degree in organic chemistry from Indiana University. After graduation, Dr. Lin went to professor Overman's group at UC Irvine to be a postdoctor fellow. After spending two years there, he joined Bayer USA as a research scientist working in the immunoscience area. Then moved to Abbott Laboratories. He spent 18 years in pharmaceutical research. His research mainly focused on neuroscience area for the first 10 years at Abbott. He identified three preclinical candidates, ABT-418, ABT-089, ABT-594 for CNS area. In Oncology area, he led the chemistry team in the Farnesyl transferase inhibitor project, and identified ABT 100 as clinical candidate. He also worked on several exploratory projects. Most notably is Chk1 project that yields many patents and publications in peer reviewed journals. Dr. Lin has 117 publications.

Peter H Rehse Ph.D. Vice President of Biology, Shanghai Medicilon Inc .
Peter Hugo Rehse, as Vice President of Medicilon since 2007. He has more than twenty year’s experience as a scientist specializing in macromolecular crystallography and analysis. He received Ph.D. in Crystallography from the University of London, England.Since gradation his projects have ranged from basic science to direct applications to the pharmaceutical industry conducted in internationally acclaimed facilities and institutes in Germany (Max Plank), Canada (NRC) and Japan (RIKEN).Just before joining Medicilon he worked for the RIKEN Protein 3000 project solving a large number of crystal structures.